Biora rises after FDA allows human trials for bowel disease treatment

Biora Therapeutics

01/12/2023 10:25

** Drug developer Biora Therapeutics' shares  BIOR.O  rise
~58% to about $2 in premarket trading 
    ** After market close on Thursday, co reported U.S. FDA
cleared its application seeking to begin clinical trials on its
drug/device combination, BT-600, for the treatment of ulcerative
colitis 
    ** Co said it will complete the activities required by FDA
and the trial site prior to enrolling the first subject in its
early-stage trial in the U.S. in the coming weeks
    ** Ulcerative colitis is an inflammatory bowel disease that
causes irritation, inflammation and ulcers in the lining of the
large intestine
    ** As of last close, stock down 62.34% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))